is expected to reach USD 660 billion in 2025
Nausea tends to peak here
Whats Next: Regulatory filing for weight management: by end of 2025 Submission for type 2 diabetes: expected in 2026 Drug discovered by Chugai, licensed by Lilly in 2018 Implication: Orforglipron could become the first once-daily oral GLP-1 therapy with potent glucose-lowering and weight-loss benefits, potentially disrupting the injectable incretin market.
Mitrofanova A, Fontanella AM, Burke GW, Merscher S, Fornoni A
The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration
I am so happy to have found VITAstir, which helps simplify my life by minimizing multiple trips to receive injections (As an experienced injector due to years of IVF and gestational diabetes, as well as IM MIC and Lipoden, the trips to the pharmacy and extra cost for the pharmacist to inject were irritating)